GlassScriptPhysician profile
Luz Rosario
NPI 1225236706
$5,911.30
in general payments reported to CMS, 2019-2025
39 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 92% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.61 · 2020: $183 · 2021: $1,782 · 2022: $847 · 2023: $1,053 · 2024: $937 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,040 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,040.17 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $724.82 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Straumann USA LLC | $721.00 | 2021 | |
| Lilly USA, LLC | $719.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $692.66 | 2021-2025 | Ubrelvy, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $506.15 | 2023-2025 | |
| Pfizer INC. | $339.96 | 2021-2025 | |
| Amgen INC. | $295.53 | 2021-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $195.66 | 2022-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $189.63 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.46 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $148.28 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $141.92 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $135.50 | 2021-2025 | |
| Esperion Therapeutics, INC. | $94.00 | 2021-2025 | Nexletol |
| Neurometrix INC | $93.96 | 2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luz Rosario listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.